Human hepatitis B immunoglobulin Other names: Human antihepatitis B immunoglobulin

Therapeutic indications

Human hepatitis B immunoglobulin is indicated for:

Hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Reactivation of hepatitis B viral hepatitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Immunoprophylaxis of hepatitis B

Population group: only minors (0 - 18 years old) , adults (18 years old or older)

  • In case of accidental exposure in non-immunised subjects (including persons whose vaccination is incomplete or status unknown).
  • In haemodialysed patients, until vaccination has become effective.
  • In the newborn of a hepatitis B virus carrier-mother.
  • In subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis B.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Human hepatitis B immunoglobulin is contraindicated in the following cases:

Selective IgA deficiency

Immunoglobulin A deficiency

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.